Go Pro

MorphoSys (MOR) 10K Form and Latest SEC Filings 2026

MorphoSys logo
$18.96 0.00 (0.00%)
As of 09/17/2026

Latest MorphoSys SEC Filings & Recent Activity

MorphoSys (NASDAQ:MOR) has submitted 553+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 15-12G submitted on October 17, 2024.

DateFilerForm TypeView
10/17/2024 3:54 PM
MorphoSys (1340243) Filer
Form 15-12G
10/04/2024 3:21 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:24 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:27 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:30 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:33 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:36 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:18 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:16 PM
MorphoSys (1340243) Filer
Form POSASR
08/27/2024 9:14 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/15/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC 13D/A
08/13/2024 3:31 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
08/07/2024 3:51 PM
MorphoSys (1340243) Subject
Form SC 14D9/A
08/07/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
08/05/2024 7:14 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/02/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
08/01/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/31/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/30/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/29/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/25/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/25/2024 3:05 PM
MorphoSys (1340243) Filer
Form 25
Notification of the removal from listing and registration of matured, redeemed or retired securities  
07/18/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/18/2024 10:25 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/12/2024 3:20 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/11/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/05/2024 5:48 AM
MorphoSys (1340243) Subject
Form SC 14D9
07/05/2024 5:02 AM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T
07/02/2024 9:18 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/21/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC 13D/A
06/21/2024 9:07 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/20/2024 3:41 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/20/2024 3:33 PM
MorphoSys (1340243) Subject
Form SC14D9C
06/20/2024 2:38 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-C
06/17/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC 13D/A
06/10/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC 13D/A
06/10/2024 11:06 AM
GOLDMAN SACHS GROUP INC (886982) Filed by
MorphoSys (1340243) Subject
Form SC 13G/A
06/10/2024 10:01 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/06/2024 3:36 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/05/2024 9:22 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/04/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
Whitney Tilson: “A New Kind of Civil War Begins in Less Than 100 Days” (Ad)

President Trump says AI regulation will not stop what he calls the greatest economic engine in history, bigger than oil, gold, diamonds, or the internet. Meanwhile, The New Republic reports Republicans are eager to rein in AI ahead of the midterms. Whitney Tilson, the analyst CNBC once called The Prophet for calling the dot-com crash, the Bear Stearns and Lehman collapses, and the 2009 market bottom, says a new divide begins in 100 days with major implications for portfolios. Tilson lays out what he believes could separate winning and losing portfolios over the next six months.tc pixel

Watch Whitney Tilson's urgent briefing and prepare your portfolio now
06/04/2024 9:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/31/2024 9:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/29/2024 9:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/28/2024 9:16 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2024 9:13 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/23/2024 1:19 PM
MorphoSys (1340243) Subject
Form SC 14D9/A
05/23/2024 9:11 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/23/2024 8:04 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/21/2024 9:07 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/17/2024 9:15 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/16/2024 3:43 PM
MorphoSys (1340243) Subject
Form SC 14D9/A
05/16/2024 3:31 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
05/16/2024 9:11 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2024 9:09 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/14/2024 9:27 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/13/2024 9:19 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/10/2024 9:31 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/08/2024 9:08 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/07/2024 3:45 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
05/07/2024 9:24 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
05/06/2024 9:07 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/03/2024 9:29 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/02/2024 3:31 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
05/02/2024 9:43 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2024 9:07 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2024 7:57 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2024 3:15 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2024 9:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/26/2024 9:11 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/25/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
04/25/2024 9:38 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/24/2024 10:03 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2024 9:14 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/22/2024 9:32 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/19/2024 9:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/18/2024 3:31 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
04/18/2024 1:33 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC 13D
04/18/2024 9:13 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/17/2024 3:49 PM
MorphoSys (1340243) Subject
Form SC 14D9/A
04/17/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
04/16/2024 4:07 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
04/16/2024 9:12 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2024 2:44 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
04/12/2024 9:54 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/11/2024 10:57 AM
MorphoSys (1340243) Subject
Form SC 14D9
04/11/2024 5:01 AM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T
04/09/2024 9:07 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/08/2024 9:19 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/04/2024 9:15 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
The case for $20,000 gold before year end (Ad)

President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.tc pixel

Read the full gold report and see Eifrig's top pick now
04/02/2024 9:08 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2024 12:16 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/26/2024 10:15 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/25/2024 10:37 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/22/2024 10:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/22/2024 5:47 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/21/2024 10:27 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/20/2024 3:12 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/20/2024 10:13 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

MorphoSys SEC Filings - Frequently Asked Questions

MorphoSys (MOR) has submitted 553+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

MorphoSys's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 15-12G submitted on October 17, 2024. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:MOR are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 10/17/2024. New filings are added as they're published.
From Our Partners